Precision Medicine in Oncology
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Oncology Nursing News
Special Reports in Personalized Cancer Care
SELECT A TOPIC
Attend An Event
State of the Science Summit
Regional Seminar Series
Giants of Cancer Care
Precision Medicine in Oncology
<< View More Conferences
2017 ASH Annual Meeting and Exposition
Oncology Conference Multimedia
View more videos >>
Dr. Berdeja Discusses Next Steps With bb2121 in Multiple Myeloma
Dr. Locke on the ZUMA-6 Trial of Axi-Cel With Atezolizumab for DLBCL
Dr. Pemmaraju on Clinical Trial Results of LCL161 in High-Risk Myelofibrosis
Oncology Conference Articles
Axi-Cel Plus Atezolizumab Active, Safe in DLBCL
The combination of the CAR T-cell therapy axicabtagene ciloleucel and the PD-L1 inhibitor atezolizumab was highly active with a manageable safety profile in patients with refractory DLBCL enrolled in the phase I/II ZUMA-6 trial.
Interferon Continues to Show Promise as Myelofibrosis Option
Patients with myeloproliferative neoplasm‒associated myelofibrosis had prolonged treatment duration and improved survival compared with historical controls when treated with pegylated interferon alfa-2a.
High Response Rate in Histiocytic Disease With MEK Inhibition
The MEK inhibitor cobimetinib (Cotellic) led to objective responses in 14 of 16 patients with
-mutated and wild-type histiocytic disorders.
Ropeginterferon Alfa-2b Demonstrates Durable Activity in Polycythemia Vera
Two-year findings from the follow-up phase III CONTI-PV randomized trial showed that ropeginterferon alfa-2b, a novel pegylated formulation of interferon alfa-2b, reached a significantly higher rate of complete hematologic response versus hydroxyurea in patients with polycythemia vera.
Pegylated Interferon Alfa-2a Shows Promise in MPNs
About two-thirds of patients with hydroxyurea-resistant/intolerant polycythemia vera or high-risk essential thrombocytopenia had objective responses to pegylated interferon alfa-2a.
Venetoclax Combo Reaches High CR Rate in Older AML Patients
Two-thirds of older patients with acute myeloid leukemia achieved complete responses with the combination of venetoclax (Venclexta) and cytarabine.
Ruxolitinib Retains Benefit in Polycythemia Vera With Longer Follow-Up
Responses to ruxolitinib (Jakafi) in patients with polycythemia vera were maintained by a majority of primary responders at 4 years’ follow-up.
Selinexor Highly Active in Relapsed/Refractory AML
Almost half of patients with relapsed/refractory acute myeloid leukemia achieved complete response with the combination of selinexor (KPT-330) and AraC-containing chemotherapy.
Selinexor Combo Highly Active in Relapsed/Refractory Myeloma
Selinexor combined with weekly bortezomib and low-dose dexamethasone produced rapid and durable responses in a dose escalation/expansion trial of patients with relapsed/refractory multiple myeloma.
Promising Results in CLL for Frontline Ibrutinib Plus Chemoimmunotherapy
Adding ibrutinib to a standard frontline chemoimmunotherapy for chronic lymphocytic leukemia induced negative minimum residual disease status in bone marrow for 83% of patients.
New Analysis Confirms Carfilzomib Survival Benefit in Relapsed/Refractory Myeloma
The addition of carfilzomib to lenalidomide and dexamethasone for relapsed/refractory multiple myeloma led to a statistically significant 21% reduction in the risk for death compared with lenalidomide and dexamethasone.
Goy Reflects on MCL Data Presented at ASH 2017
Andre Goy, MD, sheds light on some studies as well as future treatment options for patients with mantle cell lymphoma (MCL).
BCMA Antibody-Drug Conjugate Reaches 60% Response in Myeloma
The B-cell maturation antigen antibody-drug conjugate GSK2857916 induced an overall response rate of 60% in heavily pretreated patients with multiple myeloma.
Elotuzumab/Lenalidomide Maintenance Deepens Responses After Transplant in Myeloma
Maintenance therapy with elotuzumab (Empliciti) and lenalidomide (Revlimid) after autologous stem cell transplant improves the quality of response achieved with induction therapy in patients with multiple myeloma.
Ivosidenib Shows High Single-Agent Activity for IDH1-mutant AML
The IDH1 inhibitor ivosidenib induced a complete response (CR) or CR with partial hematologic recovery for 30.4% of patients with relapsed/refractory
-mutant acute myeloid leukemia.
Oral Anticoagulant Equivalent to Injectable for Cancer VTE
Patients with cancer who have venous thromboembolism had similar rates of recurrent VTE or bleeding with the oral factor Xa inhibitor edoxaban (Savaysa) or the low-molecular weight heparin dalteparin (Fragmin).
Daratumumab Demonstrates Single-Agent Activity in Smoldering Myeloma
Daratumumab (Darzalex) displayed single-agent activity in intermediate- and high-risk smoldering multiple myeloma, according to results from the phase II CENTAURUS study.
Daratumumab Plus VMP New Standard of Care for Some Newly Diagnosed Myeloma Patients
The addition of daratumumab to bortezomib, melphalan, and prednisone (VMP) reduced the risk of progression or death by 50% compared with VMP alone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Venetoclax/Rituximab Hits Over 80% 2-Year PFS Rate in CLL
The combination of venetoclax and rituximab reduced the risk of disease progression or death by 83% versus bendamustine plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.
Liso-Cel CR Rate Hits 63% for Relapsed/Refractory DLBCL
Liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an objective response rate of 81% with a complete remission rate of 63% in patients with relapsed/refractory diffuse large B-cell lymphoma.
Atezolizumab Triplet Achieves 75% CR Rate in Frontline Follicular Lymphoma
The frontline combination of atezolizumab, obinutuzumab, and bendamustine, achieved a complete response in 75% of patients with follicular lymphoma, according to findings from a phase Ib/II trial.
Combination Regimen Safe, Effective as Salvage Therapy for Relapsed/Refractory Hodgkin Lymphoma
Brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) appeared active and well tolerated for the treatment of patients with relapsed/refractory Hodgkin lymphoma.
Rituximab Leads to Faster Response in CLL, But PFS Not Improved
Despite a faster time to complete remission, the addition of rituximab (Rituxan) to ibrutinib (Imbruvica) did not improve PFS or overall survival OS compared with ibrutinib alone in patients with CLL.
Acalabrutinib Highly Effective for Refractory MCL
Acalabrutinib demonstrated an objective response rate of 81% with a complete response rate of 40% for patients with refractory mantle cell lymphoma.
Curative Approach Improves Responses in Patients With Smoldering Multiple Myeloma
A novel approach demonstrated durable responses in the treatment of patients with smoldering multiple myeloma, according to results from a single-arm, phase II trial.
PD-1 Inhibitor Cemiplimab Active in B-Lymphoid Malignancies
Cemiplimab as a monotherapy and in combination with the monoclonal antibody REGN1979 demonstrated clinical activity in patients with B-cell non-Hodgkin lymphoma and Hodgkin lymphoma.
Axi-Cel Responses Sustained With Longer Follow-Up for NHL
Axi-cel (axicabtagene ciloleucel; Yescarta) maintained a complete remission rate of 40% with a median follow-up of 15.4 months for patients with refractory, aggressive non-Hodgkin lymphoma.
Tisagenlecleucel Continues to Impress in DLBCL
The CAR T-cell therapy tisagenlecleucel (Kymriah) achieved an overall response rate of 53.1% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.
BCMA-Directed bb2121 Highly Effective for Myeloma
Treatment with the BCMA-directed CAR T-cell therapy bb2121 induced complete remissions for 56% of patients with relapsed/refractory multiple myeloma.
Frontline Brentuximab Vedotin With AVD Bests ABVD for Advanced HL
The phase III ECHELON-1 study in Hodgkin lymphoma compared the use of A+AVD with standard chemotherapy of doxorubicin, bleomycin, vinblastine, and dacarbazine.
Alternative Agent Shows Clinical Activity in Patients With Advanced Systemic Mastocytosis
Treatment using BLU-285 (Avapritinib) induced clinically significant activity in patients with an advanced or aggressive form of systemic mastocytosis, according to data from an ongoing phase I trial.
Ibrutinib/Venetoclax Combo Impresses in Early CLL Data
The combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) elicited a complete response (CR) or CR with incomplete hematologic recovery rate of 47% for patients with relapsed/refractory chronic lymphocytic leukemia.
Mogamulizumab Significantly Improves PFS in CTCL
The anti-CCR4 monoclonal antibody mogamulizumab reduced the risk of progression or death by 47% compared with vorinostat (Zolinza) in previously treated patients with cutaneous T-cell lymphoma.
Zanubrutinib Highly Active in Non-Hodgkin Lymphoma
The investigational BTK inhibitor zanubrutinib (BGB-3111) demonstrated promising clinical activity in patients with non-Hodgkin lymphoma.
Lenalidomide Plus Rituximab Safe and Effective as Initial Treatment for MCL
Lenalidomide (Revlimid) plus rituximab (Rituxan) is a feasible combination that is also safe and active, as initial and maintenance therapy for patients with mantle cell lymphoma.
Direct Oral Anticoagulant Prevents VTE Recurrence in Select Patients With Cancer
Treatment using oral rivaroxaban (Xarelto) reduced venous thromboembolism (VTE) recurrence among patients with cancer, according to results from the select-d trial.
Oncology Experts Highlight Practice-Changing Abstracts at ASH 2017
Key opinion leaders share their insight on the pivotal and highly anticipated abstracts across hematologic malignancies, including lymphoma, leukemia, and multiple myeloma, ahead of 2017 ASH Annual Meeting and exactly how these findings could be implemented in and affect clinical practice.
Breakthrough Status in Lung Cancer, Fast Track Status in Lung Cancer, and 2019 WCLC Highlights
Genetic Testing Gaining Larger Role in Prostate Cancer
FDA Approves Lenvatinib/Pembrolizumab Combo for Advanced Endometrial Cancer
Secondary Cancer Risk Remains an Unresolved Issue in CLL
Elements of Treatment Discontinuation Weighed in CML
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2019
Intellisphere, LLC. All Rights Reserved.